Target Discovery

News

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

News

CRUK scientists find new tool to test lung cancer therapies

Researchers in the UK have developed a lung cancer cell line that they believe could be an important new tool for the discovery of new therapies.

News

World's largest proteomics trial launched by UK Biobank

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today.

News

AI firm Generate signs $1bn discovery deal with Novartis

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.

News

Study finds hundreds of overlooked cancer drug targets

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be use

News

AZ's Alexion inks wide-ranging AI agreement with Verge

AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that

AstraZeneca joins Tempus, Pathos in cancer AI project

CRUK scientists find new tool to test lung cancer therapies

World's largest proteomics trial launched by UK Biobank

AI firm Generate signs $1bn discovery deal with Novartis

Study finds hundreds of overlooked cancer drug targets

AZ's Alexion inks wide-ranging AI agreement with Verge

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Target Discovery

Editor's Picks